159 related articles for article (PubMed ID: 34294772)
1. Quantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria.
Narita K; Miura D; Tsushima T; Terao T; Kuzume A; Tabata R; Takeuchi M; Matsue K
Sci Rep; 2021 Jul; 11(1):14956. PubMed ID: 34294772
[TBL] [Abstract][Full Text] [Related]
2. Quantification of bone-marrow plasma cell levels using various International Myeloma Working Group response criteria in patients with multiple myeloma.
Narita K; Kobayashi H; Abe Y; Kitadate H; Takeuchi M; Matsue K
Int J Hematol; 2018 Oct; 108(4):371-374. PubMed ID: 29978432
[TBL] [Abstract][Full Text] [Related]
3. Flow cytometry remission by Ig light chains ratio is a powerful marker of outcome in multiple myeloma after tandem autologous transplant: a real-life study.
Cordone I; Marchesi F; Masi S; Summa V; Pisani F; Merola R; Cigliana G; Orlandi G; Gumenyuk S; Palombi F; Romano A; Spadea A; Renzi D; Papa E; Canfora M; Conti L; Petti MC; Mengarelli A
J Exp Clin Cancer Res; 2016 Mar; 35():49. PubMed ID: 26992692
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
[TBL] [Abstract][Full Text] [Related]
5. [The significance of serum IgD quantitation for evaluation of clinical efficacy in IgD multiple myeloma].
He J; Zhang H; Jiang H; Zeng T; Chang H; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2016 Apr; 37(4):288-91. PubMed ID: 27093990
[TBL] [Abstract][Full Text] [Related]
6. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics.
Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
Biol Blood Marrow Transplant; 2017 Apr; 23(4):598-605. PubMed ID: 28115277
[TBL] [Abstract][Full Text] [Related]
7. The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements.
Cedena MT; Martin-Clavero E; Wong S; Shah N; Bahri N; Alonso R; Barcenas C; Valeri A; Salazar Tabares J; Sanchez-Pina J; Cuellar C; Martin T; Wolf J; Lahuerta JJ; Martinez-Lopez J
PLoS One; 2020; 15(8):e0237155. PubMed ID: 32866200
[TBL] [Abstract][Full Text] [Related]
8. Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis.
Li H; Li F; Zhou X; Mei J; Song P; An Z; Zhao Q; Guo X; Wang X; Zhai Y
Ann Hematol; 2019 May; 98(5):1185-1195. PubMed ID: 30721336
[TBL] [Abstract][Full Text] [Related]
9. Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma.
Martin T; Mikhael J; Hajek R; Kim K; Suzuki K; Hulin C; Garg M; Quach H; Sia H; George A; Konstantinova T; Risse ML; Asset G; Macé S; van de Velde H; Moreau P
Blood Adv; 2022 Aug; 6(15):4506-4515. PubMed ID: 35594559
[TBL] [Abstract][Full Text] [Related]
10. Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma.
Kapoor P; Kumar SK; Dispenzieri A; Lacy MQ; Buadi F; Dingli D; Russell SJ; Hayman SR; Witzig TE; Lust JA; Leung N; Lin Y; Zeldenrust SR; McCurdy A; Greipp PR; Kyle RA; Rajkumar SV; Gertz MA
J Clin Oncol; 2013 Dec; 31(36):4529-35. PubMed ID: 24248686
[TBL] [Abstract][Full Text] [Related]
11. Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality.
Martínez-López J; Paiva B; López-Anglada L; Mateos MV; Cedena T; Vidríales MB; Sáez-Gómez MA; Contreras T; Oriol A; Rapado I; Teruel AI; Cordón L; Blanchard MJ; Bengoechea E; Palomera L; de Arriba F; Cueto-Felgueroso C; Orfao A; Bladé J; San Miguel JF; Lahuerta JJ;
Blood; 2015 Aug; 126(7):858-62. PubMed ID: 26089396
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of immunophenotypic complete response in patients with multiple myeloma achieving better than complete response.
Fukumoto K; Fujisawa M; Suehara Y; Narita KT; Usui Y; Takeuchi M; Matsue K
Leuk Lymphoma; 2016 Aug; 57(8):1786-92. PubMed ID: 26764045
[TBL] [Abstract][Full Text] [Related]
13. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.
Flores-Montero J; Sanoja-Flores L; Paiva B; Puig N; García-Sánchez O; Böttcher S; van der Velden VHJ; Pérez-Morán JJ; Vidriales MB; García-Sanz R; Jimenez C; González M; Martínez-López J; Corral-Mateos A; Grigore GE; Fluxá R; Pontes R; Caetano J; Sedek L; Del Cañizo MC; Bladé J; Lahuerta JJ; Aguilar C; Bárez A; García-Mateo A; Labrador J; Leoz P; Aguilera-Sanz C; San-Miguel J; Mateos MV; Durie B; van Dongen JJM; Orfao A
Leukemia; 2017 Oct; 31(10):2094-2103. PubMed ID: 28104919
[TBL] [Abstract][Full Text] [Related]
14. Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients.
Michallet M; Chapuis-Cellier C; Dejoie T; Lombard C; Caillon H; Sobh M; Moreau P; Attal M; Avet-Loiseau H
Leukemia; 2018 Feb; 32(2):376-382. PubMed ID: 28663581
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S
Cancer; 2010 Jul; 116(13):3143-51. PubMed ID: 20564642
[TBL] [Abstract][Full Text] [Related]
16. oligoclonal bands in patients with multiple myeloma: its emergence per se could not be translated to improved survival.
Fujisawa M; Seike K; Fukumoto K; Suehara Y; Fukaya M; Sugihara H; Takeuchi M; Matsue K
Cancer Sci; 2014 Nov; 105(11):1442-6. PubMed ID: 25182124
[TBL] [Abstract][Full Text] [Related]
17. Response rates and minimal residual disease outcomes as potential surrogates for progression-free survival in newly diagnosed multiple myeloma.
Daniele P; Mamolo C; Cappelleri JC; Bell T; Neuhof A; Tremblay G; Musat M; Forsythe A
PLoS One; 2022; 17(5):e0267979. PubMed ID: 35550641
[TBL] [Abstract][Full Text] [Related]
18. Can urine studies be replaced by serum free light chains measurements to assign responses in multiple myeloma patients?
Cárdenas MC; Iñigo B; Ortega I; Palomar MA; Menéndez M; Plaza P; Martínez-Novillo M; Benavente C
Front Oncol; 2022; 12():1056293. PubMed ID: 36531081
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy.
Tschautscher MA; Jevremovic D; Rajkumar V; Dispenzieri A; Lacy MQ; Gertz MA; Buadi FK; Dingli D; Hwa YL; Fonder AL; Hobbs MA; Hayman SR; Zeldenrust SR; Lust JA; Russell SJ; Leung N; Kapoor P; Go RS; Lin Y; Gonsalves WI; Kourelis T; Warsame R; Kyle RA; Kumar SK
Am J Hematol; 2019 Jul; 94(7):751-756. PubMed ID: 30945330
[TBL] [Abstract][Full Text] [Related]
20. [Impact of minimal residual disease detection after treatment of multiple myeloma].
Szendrei T; Plander M; Szabó Z; Kereskai L; Kajtár B; Papp G; Iványi JL
Orv Hetil; 2019 Mar; 160(13):502-508. PubMed ID: 30907098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]